ADHD Medication During Pregnancy and Breastfeeding
The choice of whether to stop or continue ADHD medications during pregnancy and breastfeeding is a challenge for women suffering from the condition. There are few data regarding how exposure over time may affect a pregnant fetus.
A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems such as impaired hearing or vision, febrile seizures, or IQ impairment. The authors acknowledge that more high quality research is needed.
Risk/Benefit Analysis
Women who are expecting and taking ADHD medication should evaluate the benefits of using it versus the dangers for the baby. Physicians do not have the data needed to provide clear recommendations, but they can provide information on benefits and risks that can assist pregnant women in making informed decisions.
A study published in Molecular Psychiatry concluded that women who took ADHD medication during their early pregnancy were not at higher risk of fetal malformations, or structural birth defects. Researchers used a vast, population-based case-control study to evaluate the incidence of major structural birth defects in infants born to mothers who took stimulants during the early stages of pregnancy, and those who did not. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure accurate case classification and to minimize the possibility of bias.
However, the researchers' study was not without its flaws. Most important, they were unable to distinguish the effects of the medication from those of the disorder that is underlying. adult add medication makes it difficult to know whether the small associations observed in the exposed groups result from medication use or the confounding effect of comorbidities. Additionally the researchers did not look at the long-term outcomes of offspring.
The study revealed that infants whose mothers had taken ADHD medication during pregnancy had a greater risk of being admitted to the neonatal care unit (NICU), compared to mothers who didn't take any medication during pregnancy or quit taking the medication prior to or during pregnancy. This was due to central nervous system-related disorders and the higher risk of admission did not appear to be influenced by which stimulant medications were taken during pregnancy.
Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having caesarean sections or a baby that scored low on the Apgar scale (less than 7). These increases appeared to be unrelated to the type of medication used during pregnancy.
The researchers suggest that the risk of a small amount with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefits to both the mother and child from continued treatment for the woman's condition. Physicians should talk to their patients about this and try to help them improve coping skills which could reduce the impact of her disorder in her daily functioning and her relationships.
Medication Interactions
Many doctors are faced with the decision of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are often made without clear and reliable evidence. Instead, doctors have to weigh their own knowledge and experience, as well as the experiences of other doctors, and the research on the subject.
In particular, the issue of possible risks to the baby can be tricky. The research on this subject is based on observations rather than controlled studies and many of the findings are contradictory. In addition, most studies limit their analysis to live births, which can underestimate the severity of teratogenic effects that could cause abortion or termination of the pregnancy. The study discussed in the journal club addresses these issues by analyzing both data on live and deceased births.
The conclusion: While certain studies have demonstrated an association between ADHD medications and the risk of certain birth defects, others have found no connection, and most studies have a neutral or slight negative effect. Therefore, a careful risk/benefit analysis is required in every instance.
For many women with ADHD who suffer from ADHD, the decision to discontinue medication is difficult, if not impossible. In an article recently published in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of isolation, and family conflict for those suffering from the disorder. The loss of medication can also impact the ability to safely drive and to perform work-related tasks which are crucial aspects of daily life for those suffering from ADHD.
She recommends women who are unsure about whether or not to stop medication in light of their pregnancy should consider informing family members, friends and colleagues about the condition, its impact on daily functioning, and the advantages of staying on the current treatment regimen. Educating them can also make the woman feel more comfortable as she struggles with her decision. Certain medications can be passed through the placenta. If the patient decides not to take her ADHD medication while breastfeeding, it is crucial to be aware that the drug could be passed on to her infant.
Birth Defects and Risk of
As the use and misuse of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD) is increasing, so does concern about the potential effects of these drugs on foetuses. A study that was published in the journal Molecular Psychiatry adds to the body of information on this topic. Researchers used two massive data sets to study more than 4.3 million pregnancy and determine whether stimulant medications increased birth defects. Although the risk overall is low, the researchers found that exposure in the first trimester to ADHD medications was associated with an increased risk of specific heart defects, like ventriculo-septal defects (VSD).
The researchers of the study could not discover any connection between early use of medication and other congenital anomalies such as facial deformities or club feet. The results are in line with previous studies revealing the presence of a small, but significant increase in the risk of heart malformations among women who started taking ADHD medications prior to the time of the birth of their child. The risk grew during the latter part of pregnancy, when many women decide to stop taking their ADHD medications.
Women who took ADHD medication during the first trimester were more likely need a caesarean or have a low Apgar after birth and had a baby that required breathing assistance at birth. The researchers of the study were not able to eliminate selection bias because they limited the study to women who did not have any other medical conditions that could have contributed to the findings.
The researchers hope their research will help inform the clinical decisions of doctors who treat pregnant women. They recommend that, while discussing the risks and benefits is crucial but the decision to stop or continue medication must be based on each woman's needs and the severity of her ADHD symptoms.
The authors caution that, even though stopping the medication is a possibility to look into, it is not advised due to the high rate depression and other mental disorders among women who are pregnant or have recently given birth. Furthermore, research suggests that women who decide to stop taking their medication are more likely to experience a difficult time adapting to life without them following the birth of their baby.
Nursing
The responsibilities of being a new mom can be overwhelming. Women with ADHD who have to deal with their symptoms while attending doctor appointments as well as preparing for the arrival of their child and adjusting to new household routines may face a lot of challenges. Many women choose to continue taking their ADHD medication during pregnancy.
The risk to a breastfeeding infant is minimal because the majority of stimulant medication passes through breast milk at a low level. However, the rate of exposure to medications by the newborn can vary depending on dosage, frequency it is administered, and the time of day it is administered. Additionally, individual medications enter the infant's system differently through the gastrointestinal tract and breast milk. The impact of this on a newborn infant is not fully known.
Some doctors may decide to stop stimulant medication during a woman’s pregnancy due to the absence of research. It's a difficult choice for the woman, who must weigh the benefits of her medication against the risks to the foetus. In the meantime, until more information is available, GPs can ask pregnant patients if they have an background of ADHD or if they intend to take medication during the perinatal phase.
A increasing number of studies have shown that the majority of women are able to safely continue their ADHD medication during pregnancy and breastfeeding. In the end, many patients are choosing to do so and, in consultation with their physician, they have found that the benefits of keeping their current medication exceed any risk.
Women with ADHD who plan to breastfeed should seek advice from an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor and discuss the pros and cons of continued treatment, including non-pharmacological strategies. Psychoeducation should also be provided to help pregnant people with ADHD recognize their symptoms and the root cause, learn about available treatments and to reinforce existing strategies for coping. This should involve an approach that is multidisciplinary, including the GP as well as obstetricians, psychiatry and obstetricians. Pregnancy counseling should include a discussion of a treatment plan for the mother and the child, monitoring of signs of deterioration and, if necessary adjustments to the medication regime.